Fusion Antibodies plc (AIM:FAB)
13.16
-0.10 (-0.72%)
Jan 22, 2026, 4:26 PM GMT
Fusion Antibodies Revenue
Fusion Antibodies had revenue of 838.00K GBP in the half year ending September 30, 2025, with 54.90% growth. This brings the company's revenue in the last twelve months to 1.60M, down -11.43% year-over-year. In the fiscal year ending March 31, 2025, Fusion Antibodies had annual revenue of 1.97M with 72.98% growth.
Revenue (ttm)
1.60M
Revenue Growth
-11.43%
P/S Ratio
9.44
Revenue / Employee
66.50K
Employees
24
Market Cap
15.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.97M | 829.00K | 72.98% |
| Mar 31, 2024 | 1.14M | -1.77M | -60.84% |
| Mar 31, 2023 | 2.90M | -1.90M | -39.55% |
| Mar 31, 2022 | 4.80M | 634.00K | 15.22% |
| Mar 31, 2021 | 4.17M | 270.00K | 6.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Futura Medical | 7.93M |
| IXICO | 6.53M |
| Arecor Therapeutics | 5.06M |
| Aptamer Group | 1.20M |
| Ondine Biomedical | 1.18M |
| OptiBiotix Health | 1.15M |
| Oxford BioDynamics | 1.10M |
| ImmuPharma | -69.96K |